New drugs in myelofibrosis: Critical assessment of additional value to monotherapy with JAK inhibitors
Sign Up to like & getrecommendations! Published in 2024 at "American Journal of Hematology"
DOI: 10.1002/ajh.27248
Abstract: Ruxolitinib in combination with navitoclax or pelabresib in myelofibrosis: activity in JAKi-naïve patients. read more here.
Keywords: myelofibrosis; drugs myelofibrosis; assessment additional; critical assessment ... See more keywords